Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black PatientsA Randomized Trial

Authors:
  • DRDeJuran Richardson
    DeJuran Richardson
  • MKMichael Kelly
    Michael Kelly
  • SRSean Ruland
    Sean Ruland
  • EHElena Hung
    Elena Hung
  • YHYvonne Harris
    Yvonne Harris
  • SKSteven Kittner
    Steven Kittner
  • SLSue Leurgans
    Sue Leurgans

Abstract
Blacks are disproportionately affected by stroke, yet they have been underrepresented in clinical trials.1-8 Recommendations for stroke prevention in this population have been based largely on trials that have included few black participants. This may not be an optimal practice because blacks are among those with a higher prevalence of major cardiovascular risk factors, a different distribution of atherosclerotic occlusive cerebral vascular lesions, vascular biological differences such as low renin hypertension, and a different pattern of use of medical procedures and access to care8-13 that could influence outcome.

This publication has 18 references indexed in Scilit: